Our Research
This original clinical study article describes the use and safety of umbilical cord wharton’s
jelly derived-mesenchymal stem cell therapy for a range of indications. Human umbilical
cord Wharton’s jelly derived MSCs (hWJ-MSCs) are reported as the most potent cell source,
however they remain understudied in comparison to autologous sources. This study increases
the knowledge base on the safety of this therapy when delivered at a high dosage and via
various administration routes including intravenous, intrathecal and intraarticular injection.
Therefore, this study is directly suited to the aims and audience of CellR4, including the
fields of regenerative medicine and cell-based therapies
Brian M. Mehling, DongCheng Wu, Doreen Santora, Ellen O’Gorman,
Katarina Novakova, Germain Spencer, Charmaine Thomas, Rohan Grant, Ryan
Rutherford, Renata Mihályová